rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone(Roche / Genentech)은 FRα 표적 항체로, Diffuse Large B-Cell Lymphoma; Follicular Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targets of the E2F1 pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 76% (ClinicalTrials.gov NCT02911142). 차별점: unique capability to non-invasively quantify tumor metabolic heterogeneity.
FRα
Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
Recruiting
bispecific antibodies become more available, further improvements in s
Vedotin-Based Polatuzumab Vedotin Combined with
Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in
unique capability to non-invasively quantify tumor metabolic heterogeneity
targets of the E2F1 pathway
t cells, in part through the activation
apoptosis, reinstated antigen presentation, and reprogrammed the tumor immune landscape in both cell lines and in vivo models
Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Surviv
resistance to standard immunochemotherapy regimens [R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)]
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone(Roche / Genentech)은 FRα 표적 항체로, Diffuse Large B-Cell Lymphoma; Follicular Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targets of the E2F1 pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 76% (ClinicalTrials.gov NCT02911142). 차별점: unique capability to non-invasively quantify tumor metabolic heterogeneity.
FRα
Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
Recruiting
bispecific antibodies become more available, further improvements in s
Vedotin-Based Polatuzumab Vedotin Combined with
Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in
unique capability to non-invasively quantify tumor metabolic heterogeneity
targets of the E2F1 pathway
t cells, in part through the activation
apoptosis, reinstated antigen presentation, and reprogrammed the tumor immune landscape in both cell lines and in vivo models
Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Surviv
resistance to standard immunochemotherapy regimens [R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)]
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.